StockData

Ovid Therapeutics vs Praxis Precision Medicines

OVID and PRAX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OVID and PRAX compare

Praxis Precision Medicines is the larger company, worth 20 times as much as Ovid Therapeutics ($8.5B against $434M).

Ovid Therapeutics scores higher on the StockData Score (10 against 7 for Praxis Precision Medicines), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOVIDPRAX
Size and price
Market cap$434M$8.5B
Share price$2.22$305.06
Change, 1 year70.1%63.6%
Change, 5 years−31.9%21.4%
Beta (5Y)1.341.92
Employees23168
StockData Score
Total score10 (better)7
Valuation score1 (better)0
Growth score1 (better)0
Performance score2 (better)1
Health score66
Dividend score00
Valuation
P/S274×–
P/B2.1× (better)6.4×
FCF yield–−3.6%
Growth
Revenue growth (TTM)−76.2%–
Revenue growth, 5Y average−10.5%–
Profitability
Operating margin−3687%–
Net margin−2179%–
Return on equity−26.0% (better)−38.9%
Return on invested capital−160%–
Financial health
Debt / equity0.000.00
Current ratio12.3915.73 (better)
Altman Z-score9.41102.57 (better)
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions75.3%121%
Held by insiders13.6%0.72%
Insider net buying, 12 months−$29.3K (better)−$3.6M
Short interest, % of float10.8%15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.